Search

everythinglearnresearchcommunity

for

Search:↓

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.

The user is experiencing hair loss and is using topical finasteride, rosemary oil, caffeine, microneedling, low-level laser therapy, scalp massages, ketoconazole shampoo, and various vitamins and supplements. They are concerned about potential gynecomastia and are considering using minoxidil if current treatments do not stop hair loss or promote regrowth.

A 22-year-old is experiencing hair loss and anxiety, trying treatments like topical finasteride, rosemary oil, caffeine, microneedling, low-level laser therapy, scalp massages, ketoconazole shampoo, and various vitamins. They are concerned about potential gynecomastia and are considering using minoxidil if current treatments don't stop hair loss or promote regrowth.

User warns about finasteride causing Huge Penis Syndrome (HPS) with 2cm/year growth. Others joke about the side effect and share their experiences.

A person is microdosing estrogen for hair loss after finasteride and dutasteride failed, risking feminizing effects. Alternatives like minoxidil, RU58841, or hair transplants are suggested.

Finasteride users may have an increased risk of depression, anxiety, and suicidal thoughts, though some attribute these issues to hair loss itself. The link between finasteride and mental health effects is debated, with varying user experiences.

Finasteride helped maintain hair density and prevent further hair loss over 4.5 years, with no major side effects except mild gynecomastia. Consistency and regular health checks are recommended, and the user experienced stable hair density with occasional shedding.

The conversation discusses the effectiveness of finasteride and dutasteride in treating hair loss, emphasizing that significant results often take 12-18 months or more. Dutasteride is generally considered superior, with similar or fewer side effects than finasteride, but patience is required for noticeable improvement.

User experienced gynecomastia from finasteride and found a solution using liposomal topical finasteride. This method minimizes side effects and is effective for hair loss treatment.

A 57-year-old man with severe hair loss since age 14 tried various hair loss treatments over two years, including finasteride, dutasteride, minoxidil, and supplements, with some minor regrowth. He also experimented with topical treatments and microneedling, but results were not cosmetically significant.

A user with aggressive male pattern baldness found that topical melatonin significantly reduced their hair shedding to 1 or 2 hairs per day and noticed some thickening of side hair. They tried many treatments like finasteride and minoxidil with little success, but topical melatonin showed immediate results in reducing hair loss.

HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.

27-year-old female experiences aggressive hair thinning and hirsutism despite normal testosterone levels. Spironolactone and 2% minoxidil were ineffective; high DHEA sulfate levels may be the cause.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

A 19-year-old male switched from finasteride and minoxidil to dutasteride due to continued hair thinning and is experiencing increased nipple sensitivity and a small lump, raising concerns about gynecomastia. Suggestions include slowing the transition, checking hormone levels, and considering an aromatase inhibitor.

The conversation discusses the potential role of prolactin in hair loss and mentions treatments like HMI115, mucuna pruriens, Zinc, and B6 P5P for lowering prolactin levels. It also touches on the use of natural compounds and the lack of studies due to funding issues.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

Minoxidil may cause increased prolactin levels, leading to side effects like puffy nipples and chest tenderness. Users experienced these issues and considered stopping minoxidil while continuing or switching to other treatments like finasteride, microneedling, and supplements.

The potential of lowering prolactin levels to regrow hair, with a reference to Bayer's drug HMI 115 which has been indicated as having this effect. Treatments mentioned include Minoxidil and Finasteride, as well as RU58841.

Men with early male pattern baldness (MPB) may have hormonal abnormalities similar to those in women with PCOS. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

Hair loss in moms can be caused by hormonal changes, stress, genetics, and nutritional deficiencies. Solutions include hair toppers, Minoxidil, PRP therapy, and a healthy diet with supplements.

A 34-year-old woman is experiencing diffuse hair loss and irregular periods, possibly due to long-term spironolactone use. She is considering minoxidil and finasteride for treatment and seeking medical advice for androgenic alopecia and hormonal imbalances.

The user is experiencing breast tissue growth from taking dutasteride and minoxidil, and is considering reducing the dosage or stopping the medication. Suggestions include seeing an endocrinologist, using Raloxifene or Arimidex, and considering topical treatments or surgery if necessary.

Hair loss discussion includes potential HMI-115 treatment. Topical mucuna pruriens shows good results, blocking prolactin possibly more important than blocking DHT.

A female user is experiencing minimal regrowth and miniaturized hair after 6 months of treatment with oral minoxidil, spironolactone, and topical minoxidil. She seeks advice on whether she can restore her remaining follicles.

Minoxidil increases hair count despite high prolactin being linked to hair loss. Blocking DHT is effective, but not always necessary; HMI-115 is a promising treatment for androgenetic alopecia.